Short Interest in SCYNEXIS, Inc. (NASDAQ:SCYX) Decreases By 14.7%

SCYNEXIS, Inc. (NASDAQ:SCYX) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 678,500 shares, a decrease of 14.7% from the November 30th total of 795,400 shares. Based on an average trading volume of 163,900 shares, the short-interest ratio is presently 4.1 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of SCYNEXIS from a “sell” rating to a “hold” rating in a research note on Friday, November 8th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of SCYNEXIS by 10.0% during the third quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock worth $594,000 after purchasing an additional 36,405 shares during the period. XTX Topco Ltd acquired a new stake in SCYNEXIS during the 3rd quarter worth about $25,000. Finally, Acadian Asset Management LLC lifted its stake in SCYNEXIS by 28.4% during the second quarter. Acadian Asset Management LLC now owns 540,683 shares of the company’s stock valued at $1,080,000 after buying an additional 119,600 shares in the last quarter. Institutional investors own 54.37% of the company’s stock.

SCYNEXIS Stock Down 2.0 %

Shares of SCYNEXIS stock opened at $1.00 on Monday. The business has a fifty day simple moving average of $1.24 and a 200-day simple moving average of $1.57. SCYNEXIS has a fifty-two week low of $0.90 and a fifty-two week high of $3.07. The firm has a market cap of $37.92 million, a price-to-earnings ratio of -1.35 and a beta of 1.50.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.14. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%. The company had revenue of $0.66 million during the quarter. Analysts anticipate that SCYNEXIS will post -0.55 earnings per share for the current fiscal year.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.